drugset / Trial / NCT03709823
Trial of Cytisine in Adult Smokers
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This placebo-controlled Phase 2b trial is being conducted at sites within the United States (US) to evaluate the effectiveness cytisine dosage (1.5 mg, 3.0 mg) and administration schedule (commercial titration versus simplified 3 times daily \[TID\] schedule) within a 25-day treatment period.
Timeline
- Start
- 2018-11-13
- Primary completion
- 2019-04-23
- Completion
- 2019-04-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cytisinicline | Small molecule | 1.5 mg | — |
| Subject | Cytisinicline | Small molecule | 3 mg | — |
Indications
No indication recorded.